BeStock  

Neurocrine Biosciences NBIX

US equityMarket cap rank #1096Drug Manufacturers - Specialty & Generic
$150.57 −$6.02 (-3.84%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $150.57 0.00%
Open$156.27
Prev close$156.59
Day range$150.24 – $158.26
Volume1.59M
Market cap$15.24B
P/E (TTM)22.3
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.12B+41.2% YoY
Operating profit$343.00M+43.3% YoY
Net profit$206.50M-1.4% YoY
Diluted EPS$1.96-3.9% YoY
Free cash flow$383.60M+79.0% YoY
Operating cash flow$395.20M

Revenue, last 8 quarters

$627.7MDec '24$572.6MMar '25$687.5MJun '25$794.9MSep '25$805.5MDec '25$814.5MMar '26$959.0MJun '26$1.1BSep '26

Net profit, last 8 quarters

$103.1MDec '24$7.9MMar '25$107.5MJun '25$209.5MSep '25$153.7MDec '25$197.9MMar '26$144.4MJun '26$206.5MSep '26

Diluted EPS by quarter

1.00Dec '240.08Mar '251.06Jun '252.04Sep '251.48Dec '251.91Mar '261.39Jun '261.96Sep '26

Free cash flow by quarter

$235.2MDec '24$54.1MMar '25$89.5MJun '25$214.3MSep '25$390.8MDec '25$136.7MMar '26$128.6MJun '26$383.6MSep '26

Annual revenue

$1.0BFY20$1.1BFY21$1.5BFY22$1.9BFY23$2.4BFY24$2.9BFY25

Profitability & balance sheet

Gross margin97.7%
Operating margin24.6%
Net margin19.0%
Return on equity20.4%
Return on assets14.2%
Return on invested capital18.2%
Current ratio2.04
Liabilities / assets31.1%
Cash & investments$737.90M
Total debt$392.30M
Net cash (debt)$345.60M
Free cash flow / sales28.1%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • INGREZZA net product sales$801.50M 71.4%
  • CRENESSITY net product sales$210.80M 18.8%
  • VYKAT XR net product sales$106.70M 9.5%
  • Other revenues$3.70M 0.3%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $1.12B $959.00M $814.50M $2.86B $805.50M
Total Operating Revenue $1.12B $959.00M $814.50M $2.86B $805.50M
Cost of Revenue $26.60M $23.20M $13.80M $52.10M $20.60M
Gross Profit $1.10B $935.80M $800.70M $2.81B $784.90M
Operating Expense $753.10M $782.80M $614.70M $2.17B $557.00M
Selling and Admin Expenses $366.30M $439.70M $318.50M $1.16B $301.80M
Research & Development $351.80M $326.70M $296.20M $1.02B $258.20M
Depreciation & Amortization & Depletion $35.00M $16.40M – – –
-Depreciation & Amortization $35.00M $16.40M – – –
Operating Profit $343.00M $153.00M $186.00M $636.50M $227.90M
Net Non-Operating Interest Income (Expense) -$300,000.00 -$2.90M – $90.30M $90.30M
Non-Operating Interest Expense $300,000.00 $2.90M – – –
Other Income (Expense) -$59.00M $12.10M $60.80M -$21.40M -$78.80M
Gain on Sale of Security -$47.30M $13.60M $53.40M -$4.00M -$61.80M
Special Income (Charges) -$11.70M -$1.50M $7.40M -$17.40M -$17.00M
-Less:Other Special Charges $11.70M $1.50M $21.20M $17.40M $17.00M
-Gain on Sale Of Business $0.00 $0.00 $28.60M – –
Pretax Profit $283.70M $162.20M $246.80M $705.40M $239.40M
Tax $77.20M $17.80M $48.90M $226.80M $85.70M
Net Profit $206.50M $144.40M $197.90M $478.60M $153.70M
Profit from Continuing Operations $206.50M $144.40M $197.90M $478.60M $153.70M
Net Income to Parent Company $206.50M $144.40M $197.90M $478.60M $153.70M
Net Income to Common Stockholders $206.50M $144.40M $197.90M $478.60M $153.70M
Basic EPS $2.03 $1.43 $1.97 $4.81 $1.54
Diluted EPS $1.96 $1.39 $1.91 $4.67 $1.48
Non-Operating Interest Income – – – $90.30M –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $5.63B $5.36B $4.91B $4.63B $4.63B
Total Current Assets $2.01B $1.64B $2.44B $2.52B $2.52B
Cash and Cash Equivalents & Short-Term Investments $737.90M $389.80M $1.32B $1.48B $1.48B
-Cash and Cash Equivalents $641.50M $332.40M $266.50M $713.00M $713.00M
-Short Term Investments $96.40M $57.40M $1.05B $767.40M $767.40M
Receivables $957.30M $887.00M $768.10M $686.80M $686.80M
-Accounts Receivable $957.30M $887.00M $768.10M $686.80M $686.80M
Prepaid Assets $212.40M $217.10M $224.80M $170.70M $170.70M
Inventory $66.10M $104.20M $64.50M $69.00M $69.00M
Other Current Assets $34.50M $39.40M $62.50M $115.80M $115.80M
Total Non-Current Assets $3.62B $3.72B $2.47B $2.11B $2.11B
Net PPE $529.40M $538.50M $538.00M $545.20M $545.20M
-Gross PPE $529.40M $538.50M $538.00M $663.50M $663.50M
Investments and Advances $146.80M $239.20M $1.48B $1.18B $1.18B
-Available for Sale Securities $146.80M $239.20M $1.48B $1.18B $1.18B
Goodwill and Other Intangible Assets $2.69B $2.73B – – –
-Goodwill $500.60M $500.60M – – –
-Other Intangible Assets $2.19B $2.23B – – –
Non-Current Deferred Assets $11.80M $8.90M $381.40M $320.30M $320.30M
Other Non-Current Assets $239.60M $208.40M $73.60M $59.50M $59.50M
Total Liabilities $1.75B $1.67B $1.50B $1.38B $1.38B
Total Current Liabilities $984.60M $874.50M $831.70M $743.40M $743.40M
Payables $300.60M $256.60M $306.40M $172.90M $172.90M
-Accounts Payable $150.50M $142.00M $120.00M $104.90M $104.90M
-Total Tax Payable $150.10M $114.60M $186.40M $68.00M $68.00M
Current Accrued Expenses $137.30M $136.40M $153.60M $146.60M $146.60M
Current Provisions $316.20M $292.10M $231.30M $226.00M $226.00M
Other Current Liabilities $61.20M $66.20M $58.70M $69.10M $69.10M
Total Non-Current Liabilities $764.10M $791.00M $667.10M $635.00M $635.00M
Long Term Accounts Payable and Other Payables $266.60M $262.20M $241.30M $214.50M $214.50M
Long Term Debt and Capital Lease Obligation $392.30M $401.80M $406.20M $415.30M $415.30M
-Long Term Capital Lease Obligation $392.30M $401.80M $406.20M $415.30M $415.30M
Non-Current Deferred Liabilities $105.00M $91.50M – – –
Other Non-Current Liabilities $200,000.00 $35.50M $19.60M $5.20M $5.20M
Total Equity $3.88B $3.69B $3.41B $3.25B $3.25B
Stockholders' Equity $3.88B $3.69B $3.41B $3.25B $3.25B
Capital Stock $100,000.00 $100,000.00 $100,000.00 $100,000.00 $100,000.00
-Common Stock $100,000.00 $100,000.00 $100,000.00 $100,000.00 $100,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $3.04B $2.96B $2.82B $2.79B $2.79B
Retained Earnings $838.40M $724.00M $589.60M $447.70M $447.70M
Gains/Losses Not Affecting Retained Earnings $4.40M $5.10M $400,000.00 $13.10M $13.10M
-Accumulated Depreciation – – – -$118.30M -$118.30M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $395.20M $136.40M $145.80M $782.70M $388.40M
Net cash flow from continuing operations $395.20M $136.40M $145.80M $782.70M $388.40M
Net Income from Continuing Operations $206.50M $144.40M $197.90M $478.60M $153.70M
Gain/Loss from Continuing Operations $0.00 $5.20M -$28.60M – –
Depreciation & Depletion & Amortization $44.00M $24.80M $7.30M $30.10M $7.50M
Deferred Tax $10.60M -$25.30M -$61.10M $165.40M $48.20M
Other Non-Cash Items $7.60M $3.60M $1.40M $14.80M $3.20M
Change in Working Capital $19.90M -$80.10M -$3.00M -$128.80M $119.20M
-Change in Receivables -$70.20M -$84.30M -$81.40M -$210.50M $38.40M
-Change in Inventory $3.30M -$6.50M $4.30M -$15.30M -$3.40M
-Change in Payables and Accrued Expense $76.80M -$8.50M -$14.30M $160.20M $76.50M
-Change In Other Working Capital $10.00M $19.20M $88.40M -$63.20M $7.70M
Net cash flow from investing -$11.10M -$135.40M -$506.20M -$264.40M -$52.90M
Net Cash Flow from Continuing Investing Activities -$11.10M -$135.40M -$506.20M -$264.40M -$52.90M
Capital Expenditure -$11.60M -$7.80M -$9.10M -$34.00M $2.40M
Net Business Purchase and Sale $0.00 -$2.36B $63.20M – –
Net Investment Purchase and Sale $500,000.00 $2.23B -$560.30M -$230.40M -$55.30M
Financing Cash Flow -$75.00M $63.40M -$86.10M -$38.30M $37.30M
Net Cash Flow from Continuing Financing Activities -$75.00M $63.40M -$86.10M -$38.30M $37.30M
Net Issuance Payments Of Debt $0.00 – – $0.00 $0.00
Net Common Stock Issuance -$92.10M -$12.00M -$54.00M -$167.70M $0.00
Proceeds from Stock Option Exercised $25.30M $84.80M $23.60M $129.40M $37.30M
Net Other Financing Charges -$8.20M -$9.40M -$55.70M – –
Ending Cash Balance $648.00M $338.90M $274.50M $721.00M $721.00M
Net Change in Cash $309.10M $64.40M -$446.50M $480.00M $372.80M
Beginning Cash Balance $338.90M $274.50M $721.00M $241.00M $348.20M
Free Cash Flow $383.60M $128.60M $136.70M $748.70M $390.80M
Effect of Exchange Rate Changes – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on NBIX.

Sign in to join the discussion.

Scroll to Top